ATI-2231

N/A

Report date: 2022/05/19 14:42:28
NME

Base Information

Drug NameATI-2231
Drug Alias NameATI2231
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-activated protein kinase 2 inhibitors
TargetsMAP kinase-activated protein kinase 2
Therapy Area/IndicationsSolid tumoursMusculoskeletal DiseasesPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAclaris Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAclaris Therapeutics Inc
Inactive CompaniesWashington University School Of Medicine
Active IndicationsMusculoskeletal DiseasesPancreatic NeoplasmsBreast Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A